Promore Pharma’s Annual Report 2020 and AGM related Documents Published

STOCKHOLM, 6 May, 2021 – The 2020 Annual report of Promore Pharma AB (publ) and all AGM related documents are now available on the Company’s website.

The annual report is available in PDF format on the Company’s website at:
https://www.promorepharma.com/en/section/investors/financial-reports/

Documents related to the AGM, including previously published invitation, is available at:
https://www.promorepharma.com/en/annual-general-meeting-2021/

Printed copies of the annual report can be ordered from Promore Pharma AB, Fogdevreten 2, SE-171 65 Solna, or by e-mail: shareholders@promorepharma.com

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma’s two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.